Clinical Trial Update: Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating nebivolol for prevention of left ventricular systolic dysfunction in Duchenne muscular dystrophy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiomyopathy
• Duchenne Muscular Dystrophy
• Heart Failure

Drugs mentioned

• Nebivolol (Nebivolol)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Duchenne Muscular Dystrophy, Cardiomyopathy | Phase 3 | Status: COMPLETED